PCN220 COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.416
https://www.valueinhealthjournal.com/article/S1098-3015(19)32794-9/fulltext
Section Title :
Section Order :
10344
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32794-9&doi=10.1016/j.jval.2019.09.416